Can statins and steroids tame CAR-T's brain risks?

NCT ID NCT04514029

Ongoing Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participants and focuses on safety and feasibility, not yet on effectiveness. It is a small, single-center pilot study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Simvastatin and dexamethasone
What this could lead to: If successful, this could point toward a way to reduce serious nerve-related side effects from CAR-T therapy, making treatment safer.
What could go wrong: This is a very early, small pilot study with only 37 participants, so results may not apply widely. The drugs themselves can cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma lymphoma primary mediastinal large B-cell lymphoma toxic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.